腹腔投药器在卵巢肿瘤化疗中的应用  

The use of titanium implanted port in ovarian neoplasmas chemotherapy

作　　者：马彩玲[1] 徐英[1] 

机构地区：[1]新疆医科大学第一附属医院妇产科,新疆乌鲁木齐830054

出　　处：《新疆医科大学学报》2000年第3期236-237,共2页Journal of Xinjiang Medical University

摘　　要：目的 :研究腹腔投药器在卵巢癌化疗中的应用及化疗效果。 方法 :对 30例卵巢癌患者进行化疗 ,上皮性肿瘤采用两种化疗方案 :PAC(吡柔比星 +环磷酰胺 +卡铂 /顺铂 )或西艾克 +环磷酰胺 +卡铂 /顺铂。 2 2例患者安置腹腔投药器。结果 :30例患者至今共完成 12 3个疗程的化疗。 2 2例安置腹腔投药器的患者中 2 0例保持投药器通畅 ,穿刺成功率 10 0 %。临床完全缓解率 (CR)为 70 % ,总有效率为 78%。 结论 :经腹腔投药器腹腔化疗 (IP) ,可使卵巢肿瘤 IP简便易行 。Objective: To study the effectiveness and acceptability of chemotherapy with titanium implanted port in ovarian cancer. Methods: 30 cases of ovarian cancer were treated with chemotherapy. Epithelial ovarian cancer were divided into two groups according to different drugs: PAC (pirarubicin hydrochloride+cyclophosphamide+carboplatin/cisplatin) or vindesine sulfate+cyclophosphamide+carboplatin/cisplatin. 22 cases were set up with titanium implanted port. Results: 123 courses of chemotherapy were performed in 30 cases. Twenty of 22(90%) patients with titanium implanted port were successfully used up to now. Each was punctured smoothly. CR was 70%. General percent of effectiveness was 78%. Conclusions:Chemotherapy by titanium implanted port may improve clinical effect and enable intraperitoneal chemotherapy simple and easy to implement.

关 键 词：卵巢肿瘤 腹腔投药器 药物疗法 

分 类 号：R737.310.5[医药卫生—肿瘤] R730.53[医药卫生—临床医学]